Please ensure Javascript is enabled for purposes of website accessibility

Why Dynavax Technologies Stock Is Surging Today

By George Budwell - Mar 2, 2020 at 10:13AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Dynavax joins the race to develop a COVID-19 vaccine.

What happened

Shares of the vaccine and immunotherapy company Dynavax Technologies Corporation (DVAX 0.41%) rose by as much as 18.7% in premarket trading Monday morning. The biotech's stock is heating up in response to the news that it will collaborate with the University of Queensland as part of a Coalition for Epidemic Preparedness to develop a vaccine against the severe acute respiratory syndrome coronavirus 2 (a.k.a. SARS-CoV-2). Dynavax's shares have settled somewhat since their red-hot start in premarket action, but they are still up by 9% as of 9:45 a.m. EST today.

So what

SARS-CoV-2 has spread to more than 50 countries and taken the lives of over 3,000 people now. Combatting it is quickly becoming a top priority for governmental agencies and public health organizations across the globe. This collaboration between Dynavax and the University of Queensland is the latest offshoot of this global race to develop a safe and effective vaccine against SARS-CoV-2.

A blood vial positive for a coronavirus.

Image Source: Getty Images.

Dynavax, as a commercial-stage vaccine company, could play a vital role in the fight against this deadly respiratory ailment. Keeping with this theme, the biotech noted in this morning's press release that it will provide technical expertise, along with access to its proprietary toll-like receptor 9 agonist adjuvant CpG 1018, to support this initiative. CpG 1018 is the adjuvant used in the company's FDA-approved hepatitis B vaccine Heplisav-B, which helps to increase the vaccine's immune response.

Now what

Is Dynavax's newly announced tie-in to the SARS-CoV-2 outbreak reason enough to buy its stock? In short, this development is undoubtedly great PR for the company, but it doesn't exactly qualify as a needle-moving material event. Dynavax's investing thesis still centers squarely around Heplisav-B's commercial launch -- an effort that has gotten off to an uneven start.

That being said, it wouldn't be surprising if Dynavax did land some grant money from this SARS-CoV-2 vaccine initiative. Even then, though, the company isn't likely to get a large enough grant to significantly modify its cash runway. So while this news is a net positive overall, it isn't a particularly great reason to buy the biotech's stock today.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Dynavax Technologies Corporation Stock Quote
Dynavax Technologies Corporation
DVAX
$12.33 (0.41%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.